Drug Patents Expiring in 2035
1. Absorica Ld patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750711 | SUN PHARM | Low dose oral pharmaceutical composition of isotretinoin |
May, 2035
(11 years from now) | |
| US9700535 | SUN PHARM | Oral pharmaceutical composition of isotretinoin |
Aug, 2035
(11 years from now) | |
Drugs and Companies using ISOTRETINOIN ingredient
Market Authorisation Date: 05 November, 2019
Treatment: NA
Dosage: CAPSULE;ORAL
ABSORICA LD family patents
2. Accrufer patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9802973 | SHIELD TX | Crystalline forms of ferric maltol |
Oct, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10179120 | SHIELD TX | Dosage regimen of ferric trimaltol |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2024 |
Drugs and Companies using FERRIC MALTOL ingredient
NCE-1 date: 26 July, 2023
Market Authorisation Date: 25 July, 2019
Treatment: Method of treating iron deficiency
Dosage: CAPSULE;ORAL
ACCRUFER family patents
3. Acetadote patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8952065 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Feb, 2035
(10 years from now) | |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 23 January, 2004
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions
Dosage: INJECTABLE;INTRAVENOUS
ACETADOTE family patents
4. Adhansia Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10111839 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US9974752 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10500162 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10292938 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10507186 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10688060 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10512612 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10512613 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10568841 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10292939 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10449159 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-82) | Jun 28, 2024 |
| New Product(NP) | Feb 27, 2022 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 February, 2019
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ADHANSIA XR family patents
5. Adrenalin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119876 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
| US9295657 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
| US10130592 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 07 December, 2012
Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
ADRENALIN family patents
6. Airduo Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9066957 (Pediatric) | TEVA PHARM | Dry powder inhaler |
Apr, 2035
(10 years from now) | |
|
US9415008 (Pediatric) | TEVA PHARM | Dry powder inhaler |
Apr, 2035
(10 years from now) | |
| US9782551 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
| US9782550 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
| US10918816 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER;INHALATION
AIRDUO DIGIHALER family patents
7. Airduo Respiclick patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9066957 (Pediatric) | TEVA PHARM | Dry powder inhaler |
Apr, 2035
(10 years from now) | |
|
US9415008 (Pediatric) | TEVA PHARM | Dry powder inhaler |
Apr, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER;INHALATION
AIRDUO RESPICLICK family patents
8. Akynzeo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10233154 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| US10676440 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| US10961195 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| US9951016 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 10 October, 2014
Treatment: NA
Dosage: CAPSULE;ORAL
AKYNZEO family patents
9. Alecensa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10350214 | HOFFMANN-LA ROCHE | Preparation containing tetracyclic compound at high dose |
Apr, 2035
(11 years from now) | |
| US11433076 | HOFFMANN-LA ROCHE | Preparation containing tetracyclic compound at high dose |
Apr, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-159) | Nov 06, 2024 |
| New Indication(I-756) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-105) | Dec 11, 2022 |
| Orphan Drug Exclusivity(ODE) | Nov 06, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2020 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2019
Market Authorisation Date: 11 December, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
ALECENSA family patents
10. Alunbrig patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10385078 | TAKEDA PHARMS USA | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine |
Nov, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-142) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-300) | May 22, 2027 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| New Indication(I-847) | May 22, 2023 |
Drugs and Companies using BRIGATINIB ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET;ORAL
ALUNBRIG family patents
11. Amvuttra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(11 years from now) | |
| US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 13, 2027 |
| Orphan Drug Exclusivity(ODE-212) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN SODIUM ingredient
NCE-1 date: 13 June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION;SUBCUTANEOUS
AMVUTTRA family patents
12. Aponvie patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9974793 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US10500208 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9974742 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US9561229 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9808465 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US11173118 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US11744800 | HERON THERAPS INC | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
Sep, 2035
(11 years from now) | |
| US10953018 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US10624850 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US9974794 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 16 September, 2022
Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting; A method for preventing of post-operative nausea and vomiting
Dosage: EMULSION;INTRAVENOUS
APONVIE family patents
13. Arakoda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10342791 | 60 DEGREES PHARMS | Regimens of tafenoquine for prevention of malaria in malaria-naive subjects |
Dec, 2035
(11 years from now) | |
| US10888558 | 60 DEGREES PHARMS | Regimens of tafenoquine for prevention of malaria in malaria-naive subjects |
Dec, 2035
(11 years from now) | |
| US11744828 | 60 DEGREES PHARMS | Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 08, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
Drugs and Companies using TAFENOQUINE SUCCINATE ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 08 August, 2018
Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose
Dosage: TABLET;ORAL
ARAKODA family patents
14. Arikayce Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9895385 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
| US11446318 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
| US10251900 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
| US10751355 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-214) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in non-cystic fibrosis adults as part of a combination antibacterial drug regimen; Treating mycobacterium avium complex (mac) lung disease in ad...
Dosage: SUSPENSION, LIPOSOMAL;INHALATION
ARIKAYCE KIT family patents
15. Aristada patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238651 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(10 years from now) | |
| US11406632 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(10 years from now) | |
| US10813928 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(10 years from now) | |
| US9452131 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(10 years from now) | |
| US9526726 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous injection
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA family patents
16. Aristada Initio Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11154552 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(11 years from now) | |
| US10849894 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(11 years from now) | |
| US10688091 | ALKERMES INC | Aripiprazole prodrug composition |
Aug, 2035
(11 years from now) | |
| US10016415 | ALKERMES INC | Aripiprazole prodrug compositions |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 29 June, 2018
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA INITIO KIT family patents
17. Armonair Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9782551 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
| US9782550 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
| US10918816 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR DIGIHALER family patents
18. Armonair Respiclick patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10918816 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR RESPICLICK family patents
19. Augtyro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9714258 | BRISTOL | Diaryl macrocycles as modulators of protein kinases |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-455) | Nov 15, 2030 |
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
Drugs and Companies using REPOTRECTINIB ingredient
NCE-1 date: 16 November, 2027
Market Authorisation Date: 15 November, 2023
Treatment: NA
Dosage: CAPSULE;ORAL
AUGTYRO family patents
20. Axumin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10124079 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10716868 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10933147 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10967077 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
Drugs and Companies using FLUCICLOVINE F-18 ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment
Dosage: SOLUTION;INTRAVENOUS
AXUMIN family patents
21. Bafiertam patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10105337 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US9326947 | BANNER LIFE SCIENCES | Controlled release fumarate esters |
Feb, 2035
(10 years from now) | |
| US9517209 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US9814692 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US9636319 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US9820960 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US9636318 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US10098863 | BANNER LIFE SCIENCES | Fumarate esters |
Feb, 2035
(10 years from now) | |
| US9511043 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US9814691 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US9820961 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US10105336 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US10105335 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US9566259 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US9326965 | BANNER LIFE SCIENCES | Controlled release fumarate esters |
Feb, 2035
(10 years from now) | |
| US10918616 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Jun, 2035
(11 years from now) | |
| US10918617 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Aug, 2035
(11 years from now) | |
| US10918615 | BANNER LIFE SCIENCES | Fumarate esters |
Aug, 2035
(11 years from now) | |
| US10945985 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Aug, 2035
(11 years from now) | |
Drugs and Companies using MONOMETHYL FUMARATE ingredient
Market Authorisation Date: 28 April, 2020
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
BAFIERTAM family patents
22. Balversa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9902714 | JANSSEN BIOTECH | Quinoxaline derivatives useful as FGFR kinase modulators |
Mar, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2024 |
| New Indication(I-930) | Jan 19, 2027 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: 13 April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: NA
Dosage: TABLET;ORAL
BALVERSA family patents
23. Biktarvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9708342 | GILEAD SCIENCES INC | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10385067 | GILEAD SCIENCES INC | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate |
Jun, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-256) | Jun 18, 2026 |
| M(M-82) | Feb 24, 2024 |
| Orphan Drug Exclusivity(ODE-468) | Feb 23, 2031 |
| Orphan Drug Exclusivity(ODE-378) | Oct 07, 2028 |
| New Chemical Entity Exclusivity(NCE) | Feb 07, 2023 |
| New Patient Population(NPP) | Jun 18, 2022 |
NCE-1 date: 07 February, 2022
Market Authorisation Date: 07 October, 2021
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
BIKTARVY family patents
24. Brexafemme patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10927142 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(10 years from now) | |
| US10174074 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10370406 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2026 |
| New Indication(I-903) | Nov 30, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 01, 2031 |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
NCE-1 date: 01 June, 2030
Market Authorisation Date: 01 June, 2021
Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)
Dosage: TABLET;ORAL
BREXAFEMME family patents
25. Bunavail patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9522188 | BDSI | Abuse resistant transmucosal drug delivery device |
Apr, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 06, 2017 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: NA
Dosage: FILM;BUCCAL
BUNAVAIL family patents
26. Calquence patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(10 years from now) | |
| US11771696 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
| New Indication(I-817) | Nov 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with...
Dosage: CAPSULE;ORAL
CALQUENCE family patents
27. Calquence patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(10 years from now) | |
| US11771696 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; ...
Dosage: TABLET;ORAL
CALQUENCE family patents
28. Cinvanti patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10953018 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9974793 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9974794 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US11173118 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US9974742 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US10624850 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US10500208 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9561229 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9808465 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US11744800 | HERON THERAPS INC | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
Sep, 2035
(11 years from now) | |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 09 November, 2017
Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy
Dosage: EMULSION;INTRAVENOUS
CINVANTI family patents
29. Combogesic Iv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389416 | HIKMA | Aqueous formulation comprising paracetamol and ibuprofen |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using ACETAMINOPHEN; IBUPROFEN SODIUM ingredient
Market Authorisation Date: 17 October, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
COMBOGESIC IV family patents
30. Cyclophosphamide patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9662342 | EUGIA PHARMA SPECLTS | Formulations of cyclophosphamide liquid concentrate |
Jun, 2035
(11 years from now) | |
Drugs and Companies using CYCLOPHOSPHAMIDE ingredient
Market Authorisation Date: 25 August, 2021
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
CYCLOPHOSPHAMIDE family patents
31. Cyclophosphamide patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10849916 | DR REDDYS | Stable liquid formulations of cyclophosphamide and its impurities |
Jul, 2035
(11 years from now) | |
| US11382923 | DR REDDYS | Stable liquid formulations of cyclophosphamide and processes to prepare the same |
Dec, 2035
(11 years from now) | |
Drugs and Companies using CYCLOPHOSPHAMIDE ingredient
Market Authorisation Date: 07 June, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
CYCLOPHOSPHAMIDE family patents
32. Dayvigo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188652 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2025 |
| M(M-293) | Apr 20, 2026 |
Drugs and Companies using LEMBOREXANT ingredient
NCE-1 date: 07 April, 2024
Market Authorisation Date: 07 April, 2020
Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
Dosage: TABLET;ORAL
DAYVIGO family patents
33. Definity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10583207 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(11 years from now) | |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE;INTRAVENOUS
DEFINITY family patents
34. Definity Rt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11395856 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(11 years from now) | |
| US10022460 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10583207 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(11 years from now) | |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE;INTRAVENOUS
DEFINITY RT family patents
35. Epidiolex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11096905 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10709671 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11446258 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9956185 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11311498 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10137095 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10603288 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10111840 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10849860 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11701330 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10709674 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10966939 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9956186 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10092525 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9949937 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US10709673 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9956183 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US9956184 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11154516 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11633369 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11357741 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11766411 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(11 years from now) | |
| US11065209 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| US11400055 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| US10918608 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-216) | Sep 28, 2025 |
| Orphan Drug Exclusivity(ODE-332) | Jul 31, 2027 |
| Orphan Drug Exclusivity(ODE-326) | Jul 31, 2027 |
| M(M-270) | Oct 20, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2023 |
| New Patient Population(NPP) | Jul 31, 2023 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: 28 September, 2022
Market Authorisation Date: 28 September, 2018
Treatment: Use for the treatment of focal seizures in patients with dravet syndrome; Use for the treatment of seizures in patients with tuberous sclerosis complex; Use for the treatment of convulsive seizures in...
Dosage: SOLUTION;ORAL
EPIDIOLEX family patents
36. Ermeza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9345772 | MYLAN | Liquid levothyroxine formulations |
Feb, 2035
(10 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 29 April, 2022
Treatment: NA
Dosage: SOLUTION;ORAL
ERMEZA family patents
37. Eskata patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098910 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
| US9980983 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
| US10729720 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
| US10493103 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
| US9675639 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 14, 2020 |
Drugs and Companies using HYDROGEN PEROXIDE ingredient
Market Authorisation Date: 14 December, 2017
Treatment: Treatment of seborrheic keratoses that are raised
Dosage: SOLUTION;TOPICAL
ESKATA family patents
38. Evrysdi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-334) | Aug 07, 2027 |
| New Chemical Entity Exclusivity(NCE) | Aug 07, 2025 |
| Orphan Drug Exclusivity(ODE-400) | May 27, 2029 |
| New Patient Population(NPP) | May 27, 2025 |
| M(M-270) | Oct 03, 2026 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 07 August, 2024
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION;ORAL
EVRYSDI family patents
39. Evzio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10220158 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Mar, 2035
(10 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EVZIO family patents
40. Evzio (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10220158 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Mar, 2035
(10 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EVZIO (AUTOINJECTOR) family patents
41. Exem Foam Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9259494 | GISKIT | Composition and method for medical imaging of body cavities |
May, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 07, 2024 |
Drugs and Companies using AIR POLYMER-TYPE A ingredient
NCE-1 date: 08 November, 2023
Market Authorisation Date: 07 November, 2019
Treatment: Use in sonohysterosalpinography to assess fallopian tube patency
Dosage: FOAM;INTRAUTERINE
EXEM FOAM KIT family patents
42. Exkivity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9796712 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(11 years from now) | |
| US10227342 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2026 |
| Orphan Drug Exclusivity(ODE-374) | Sep 15, 2028 |
Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient
NCE-1 date: 15 September, 2025
Market Authorisation Date: 15 September, 2021
Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...
Dosage: CAPSULE;ORAL
EXKIVITY family patents
43. Fetroja patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10004750 | SHIONOGI INC | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949982 | SHIONOGI INC | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 14, 2029 |
| New Indication(I-844) | Sep 25, 2023 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 14 November, 2028
Market Authorisation Date: 14 November, 2019
Treatment: NA
Dosage: POWDER;INTRAVENOUS
FETROJA family patents
44. Fintepla patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10950331 | UCB INC | Control system for control of distribution of medication |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-312) | Jun 25, 2027 |
| New Indication(I-887) | Mar 25, 2025 |
| Orphan Drug Exclusivity(ODE-393) | Mar 25, 2029 |
| New Product(NP) | Jun 25, 2023 |
| Pediatric Exclusivity(PED) | Sep 25, 2029 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution
Dosage: SOLUTION;ORAL
FINTEPLA family patents
45. Firvanq Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11638692 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US10959949 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US10959948 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US10959947 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US10688046 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US10959946 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US10493028 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 26 January, 2018
Treatment: Treatment of c. difficile-associated diarrhea; Treatment of staphylococcal enterocolitis
Dosage: FOR SOLUTION;ORAL
FIRVANQ KIT family patents
46. Fruzaqla patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10519142 | TAKEDA PHARMS USA | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide |
Sep, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11046674 | TAKEDA PHARMS USA | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 30, 2028 |
Drugs and Companies using FRUQUINTINIB ingredient
NCE-1 date: 01 December, 2027
Market Authorisation Date: 08 November, 2023
Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-vegf therapy, and, if ras wild-ty...
Dosage: CAPSULE;ORAL
FRUZAQLA family patents
47. Genosyl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10737051 | VERO BIOTECH INC | Nitrogen dioxide storage device |
Oct, 2035
(11 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: NA
Dosage: GAS;INHALATION
GENOSYL family patents
48. Hetlioz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| US11760740 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| US11566011 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(11 years from now) | |
| US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(11 years from now) | |
| US11266622 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-330) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2021 |
| New Indication(I-850) | Dec 01, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-59) | Jan 31, 2021 |
Drugs and Companies using TASIMELTEON ingredient
NCE-1 date: 31 January, 2018
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by admi...
Dosage: CAPSULE;ORAL
HETLIOZ family patents
49. Hetlioz Lq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| US11760740 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| US11566011 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(11 years from now) | |
| US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(11 years from now) | |
| US11266622 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-329) | Dec 01, 2027 |
| New Product(NP) | Dec 01, 2023 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by admi...
Dosage: SUSPENSION;ORAL
HETLIOZ LQ family patents
50. Illuccix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11027031 | TELIX | Kit for radiolabelling |
Jul, 2035
(11 years from now) | |
Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient
Market Authorisation Date: 17 December, 2021
Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer
Dosage: POWDER;INTRAVENOUS
ILLUCCIX family patents
51. Imbruvica patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9795604 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(11 years from now) | |
|
US10695350 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(11 years from now) | |
|
US10463668 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
| ODE*(ODE*) | Aug 02, 2024 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| M(M-236) | Jan 25, 2022 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 16 February, 2018
Treatment: NA
Dosage: TABLET;ORAL; CAPSULE;ORAL; SUSPENSION;ORAL
IMBRUVICA family patents
52. Impoyz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855334 | PRIMUS PHARMS | Topical compositions comprising a corticosteroid |
Mar, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 28, 2020 |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: NA
Dosage: CREAM;TOPICAL
IMPOYZ family patents
53. Inlyta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570202 | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Feb, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma
Dosage: TABLET;ORAL
INLYTA family patents
54. Isturisa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(11 years from now) | |
| US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2025 |
| Orphan Drug Exclusivity(ODE-286) | Mar 06, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 06 March, 2024
Market Authorisation Date: 06 March, 2020
Treatment: Cushing's disease
Dosage: TABLET;ORAL
ISTURISA family patents
55. Jublia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478601 | BAUSCH | Applicator |
Apr, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 27, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Treatment: Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient
Dosage: SOLUTION;TOPICAL
JUBLIA family patents
56. Jylamvo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129833 | SHORLA | Methotrexate formulation |
Oct, 2035
(11 years from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 29 November, 2022
Treatment: NA
Dosage: SOLUTION;ORAL
JYLAMVO family patents
57. Kapspargo Sprinkle patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504655 | SPIL | Capsule dosage form of metoprolol succinate |
Jul, 2035
(11 years from now) | |
| US9700530 | SPIL | Capsule dosage form of metoprolol succinate |
Jul, 2035
(11 years from now) | |
Drugs and Companies using METOPROLOL SUCCINATE ingredient
Market Authorisation Date: 26 January, 2018
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
KAPSPARGO SPRINKLE family patents
58. Kengreal patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9700575 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
| US9295687 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
| US9439921 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
| US10039780 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 22, 2020 |
Drugs and Companies using CANGRELOR ingredient
NCE-1 date: 23 June, 2019
Market Authorisation Date: 22 June, 2015
Treatment: Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous inf...
Dosage: POWDER;INTRAVENOUS
KENGREAL family patents
59. Kimyrsa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 12 March, 2021
Treatment: NA
Dosage: POWDER;INTRAVENOUS
KIMYRSA family patents
60. Lenvima patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10407393 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(11 years from now) | |
| US10259791 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(11 years from now) | |
| US11186547 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-196) | Aug 15, 2025 |
| M(M-269) | Jul 21, 2024 |
| New Indication(I-868) | Aug 10, 2024 |
| M(M-272) | Dec 19, 2024 |
| Pediatric Exclusivity(PED) | Feb 15, 2026 |
| Orphan Drug Exclusivity(ODE) | Feb 13, 2022 |
| New Indication(I-734) | May 13, 2019 |
| Orphan Drug Exclusivity(ODE-87) | Feb 13, 2022 |
| New Indication(I-787) | Aug 15, 2021 |
| New Indication(I-807) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2020 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
NCE-1 date: 15 February, 2025
Market Authorisation Date: 13 February, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
LENVIMA family patents
61. Licart patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11351133 | IBSA INST BIO | Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug |
Feb, 2035
(10 years from now) | |
| US11344520 | IBSA INST BIO | Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug |
Feb, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 19, 2021 |
Drugs and Companies using DICLOFENAC EPOLAMINE ingredient
Market Authorisation Date: 19 December, 2018
Treatment: Method of treating acute pain due to minor strains, sprains, and contusions using a diclofenac patch containing heparin for once daily administration where heparin is not released
Dosage: SYSTEM;TOPICAL
LICART family patents
62. Lodoco patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11026901 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Jan, 2035
(10 years from now) | |
| US10842762 | AGEPHA PHARMA FZ | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Jan, 2035
(10 years from now) | |
| US11026900 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Jan, 2035
(10 years from now) | |
| US9744144 | AGEPHA PHARMA FZ | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Jan, 2035
(10 years from now) | |
| US10206891 | AGEPHA PHARMA FZ | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Jan, 2035
(10 years from now) | |
| US10265281 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Jan, 2035
(10 years from now) | |
| US11026899 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Jan, 2035
(10 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 16 June, 2023
Treatment: A method for treating and/or reducing the risk of acute myocardial infarction; A method of treating and/or reducing the risk of inflammation, atherosclerotic vascular disease, and cholesterol crystal ...
Dosage: TABLET;ORAL
LODOCO family patents
63. Lokelma patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10300087 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(11 years from now) | |
| US9592253 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11738044 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2023 |
| M(M-261) | Apr 24, 2023 |
Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient
NCE-1 date: 18 May, 2022
Market Authorisation Date: 18 May, 2018
Treatment: Treatment of hyperkalemia in adults
Dosage: FOR SUSPENSION;ORAL
LOKELMA family patents
64. Lonhala Magnair Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376661 | SUMITOMO PHARMA AM | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;INHALATION
LONHALA MAGNAIR KIT family patents
65. Mavyret patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE48923 | ABBVIE | Crystal forms |
May, 2035
(11 years from now) | |
| US9321807 | ABBVIE | Crystal forms |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE48923 (Pediatric) | ABBVIE | Crystal forms |
Nov, 2035
(11 years from now) | |
|
US9321807 (Pediatric) | ABBVIE | Crystal forms |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-232) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-233) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-372) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
| M(M-259) | Apr 10, 2023 |
| M(M-230) | Aug 06, 2021 |
| New Patient Population(NPP) | Apr 30, 2022 |
| New Dosing Schedule(D-175) | Sep 26, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2022 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: TABLET;ORAL; PELLETS;ORAL
MAVYRET family patents
66. Narcan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9468747 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
| US9629965 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
| US9480644 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
| US9775838 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
| US10085937 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
| US9707226 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
| US9561177 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
| US9211253 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 January, 2017
Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
Dosage: SPRAY, METERED;NASAL
NARCAN family patents
67. Nityr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10328029 | CYCLE | Pharmaceutical composition |
Jan, 2035
(10 years from now) | |
Drugs and Companies using NITISINONE ingredient
Market Authorisation Date: 26 July, 2017
Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
Dosage: TABLET;ORAL
NITYR family patents
68. Obredon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10105324 | SOVEREIGN PHARMS | Immediate release oral guaifenesin solution |
Nov, 2035
(11 years from now) | |
| US9549907 | SOVEREIGN PHARMS | Immediate release oral guaifenesin solution |
Nov, 2035
(11 years from now) | |
| US9808431 | SOVEREIGN PHARMS | Immediate release oral guaifenesin solution |
Nov, 2035
(11 years from now) | |
Drugs and Companies using GUAIFENESIN; HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 14 November, 2014
Treatment: A method of increasing the bioavailability of guaifenesin in a solution containing 54% to 66% by weight of propylene glycol and glycerol, wherein the method increases the cmax by at least 1.5 and/or i...
Dosage: SOLUTION;ORAL
OBREDON family patents
69. Ojjaara patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE48285 | GLAXOSMITHKLINE | N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9809559 | GLAXOSMITHKLINE | (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide |
Jun, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-441) | Sep 15, 2030 |
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2028 |
Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 16 September, 2027
Market Authorisation Date: 15 September, 2023
Treatment: For the treatment of intermediate or high-risk myelofibrosis
Dosage: TABLET;ORAL
OJJAARA family patents
70. Omlonti patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10774072 | VISIOX PHARMA | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10179127 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
| US9415038 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
| USRE48183 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
| US10765750 | VISIOX PHARMA | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
| US11793798 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
| US11197849 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
| US10702511 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 22 September, 2026
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION;OPHTHALMIC
OMLONTI family patents
71. Ongentys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357468 | NEUROCRINE | Medicaments for slowing Parkinson's disease |
May, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease
Dosage: CAPSULE;ORAL
ONGENTYS family patents
72. Onpattro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11079379 | ALNYLAM PHARMS INC | Methods of treating transthyretin (TTR) mediated amyloidosis |
Aug, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION;INTRAVENOUS
ONPATTRO family patents
73. Opfolda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10208299 | AMICUS THERAP US | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Sep, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10961522 | AMICUS THERAP US | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Sep, 2035
(11 years from now) | |
| US11753632 | AMICUS THERAP US | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2026 |
Drugs and Companies using MIGLUSTAT ingredient
Market Authorisation Date: 28 September, 2023
Treatment: The treatment of pompe patients
Dosage: CAPSULE;ORAL
OPFOLDA family patents
74. Orbactiv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 06 August, 2014
Treatment: NA
Dosage: POWDER;INTRAVENOUS
ORBACTIV family patents
75. Orladeyo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
| US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11708333 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
| US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
| US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: 03 December, 2024
Market Authorisation Date: 03 December, 2020
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older
Dosage: CAPSULE;ORAL
ORLADEYO family patents
76. Otiprio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9220796 | ALK ABELLO | Sterilization of ciprofloxacin composition |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 10, 2018 |
| New Indication(I-770) | Mar 02, 2021 |
Drugs and Companies using CIPROFLOXACIN ingredient
Market Authorisation Date: 10 December, 2015
Treatment: NA
Dosage: INJECTABLE, SUSPENSION;OTIC
OTIPRIO family patents
77. Oxbryta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9447071 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10722502 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(10 years from now) | |
| US11452720 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2024 |
| Orphan Drug Exclusivity(ODE-394) | Dec 17, 2028 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: 26 November, 2023
Market Authorisation Date: 17 December, 2021
Treatment: Treating sickle cell disease by administering voxelotor and another active agent
Dosage: TABLET, FOR SUSPENSION;ORAL; TABLET;ORAL
OXBRYTA family patents
78. Oxlumo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(11 years from now) | |
| US10612027 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(11 years from now) | |
| US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(11 years from now) | |
| US10478500 | ALNYLAM PHARMS INC | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression |
Oct, 2035
(11 years from now) | |
| US11446380 | ALNYLAM PHARMS INC | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-339) | Nov 23, 2027 |
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2025 |
| Orphan Drug Exclusivity(ODE-415) | Oct 06, 2029 |
| New Indication(I-901) | Oct 06, 2025 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
NCE-1 date: 23 November, 2024
Market Authorisation Date: 23 November, 2020
Treatment: Treatment of primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION;SUBCUTANEOUS
OXLUMO family patents
79. Pemazyre patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9611267 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| Orphan Drug Exclusivity(ODE-292) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-404) | Aug 26, 2029 |
| New Indication(I-899) | Aug 26, 2025 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: NA
Dosage: TABLET;ORAL
PEMAZYRE family patents
80. Pemetrexed patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11147817 | SHILPA | Pharmaceutical composition of pemetrexed |
Mar, 2035
(10 years from now) | |
Drugs and Companies using PEMETREXED DISODIUM ingredient
Market Authorisation Date: 22 May, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
PEMETREXED family patents
81. Pemfexy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9604990 | EAGLE PHARMS | Crystalline forms of pemetrexed diacid and manufacturing processes therefor |
Oct, 2035
(11 years from now) | |
Drugs and Companies using PEMETREXED ingredient
Market Authorisation Date: 08 February, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
PEMFEXY family patents
82. Ponvory patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10220023 | JANSSEN PHARMS | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titratio...
Dosage: TABLET;ORAL
PONVORY family patents
83. Proair Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9782550 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
| US9782551 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
| US10918816 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED;INHALATION
PROAIR DIGIHALER family patents
84. Proair Respiclick patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9782550 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
| US9782551 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED;INHALATION
PROAIR RESPICLICK family patents
85. Qalsody patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10385341 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10669546 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(10 years from now) | |
| US10968453 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-432) | Apr 25, 2030 |
| New Chemical Entity Exclusivity(NCE) | Apr 25, 2028 |
Drugs and Companies using TOFERSEN ingredient
NCE-1 date: 26 April, 2027
Market Authorisation Date: 25 April, 2023
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults who have a mutation in the superoxide dismutase 1 (sod1) gene
Dosage: SOLUTION;INTRATHECAL
QALSODY family patents
86. Qbrelis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9463183 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US11179434 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US9814751 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US11771733 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US10406199 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US9616096 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US10039800 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US10940177 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US10265370 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
Drugs and Companies using LISINOPRIL ingredient
Market Authorisation Date: 29 July, 2016
Treatment: Acute myocardial infarction; Method of treatment of heart failure; Method of treating hypertension
Dosage: SOLUTION;ORAL
QBRELIS family patents
87. Qulipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: NA
Dosage: TABLET;ORAL
QULIPTA family patents
88. Rezlidhia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9834539 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10414752 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| US10550098 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| US11498913 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-413) | Dec 01, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 01 December, 2026
Market Authorisation Date: 01 December, 2022
Treatment: A method of treating a cancer where the cancer is acute myeloid leukemia (aml)
Dosage: CAPSULE;ORAL
REZLIDHIA family patents
89. Rezurock patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11311541 | KADMON PHARMS LLC | Treatment of GVHD |
Apr, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity(ODE-362) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: 16 July, 2025
Market Authorisation Date: 16 July, 2021
Treatment: Treatment of adults and pediatric patients 12 and older with sclerodermatous form of chronic graft-versus-host disease ( cgvhd) after failure of at least two prior lines of systemic therapy
Dosage: TABLET;ORAL
REZUROCK family patents
90. Rhofade patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10751325 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US11517560 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US10335391 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US9974773 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 18, 2020 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: Once daily topical treatment of persistent facial erythema associated with rosacea in adults; Once daily topical treatment of persistent facial erythema associated with rosacea in female adults; Once ...
Dosage: CREAM;TOPICAL
RHOFADE family patents
91. Riomet Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9962336 | SUN PHARM | Extended release suspension compositions |
May, 2035
(11 years from now) | |
Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 29 August, 2019
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
RIOMET ER family patents
92. Rivfloza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11359203 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
| US10351854 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
| US10738311 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
| US11053502 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-443) | Sep 29, 2030 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2028 |
Drugs and Companies using NEDOSIRAN SODIUM ingredient
NCE-1 date: 30 September, 2027
Market Authorisation Date: 29 September, 2023
Treatment: Method of treating primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION;INJECTION
RIVFLOZA family patents
93. Rozlytrek patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10231965 | GENENTECH INC | Molecules for administration to ROS1 mutant cancer cells |
Feb, 2035
(10 years from now) | |
| US10561651 | GENENTECH INC | Methods for treating neuroblastoma |
Feb, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-265) | Aug 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 15, 2024 |
| Orphan Drug Exclusivity(ODE-313) | Aug 15, 2026 |
| New Patient Population(NPP) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-448) | Oct 20, 2030 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 16 August, 2023
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion
Dosage: CAPSULE;ORAL
ROZLYTREK family patents
94. Rubraca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9987285 | ZR PHARMA | High dosage strength tablets of rucaparib |
Aug, 2035
(11 years from now) | |
| US10130636 | ZR PHARMA | High dosage strength tablets of rucaparib |
Aug, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-168) | Apr 06, 2025 |
| Orphan Drug Exclusivity(ODE-126) | Dec 19, 2023 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2021 |
| New Indication(I-830) | May 15, 2023 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2023 |
| New Indication(I-772) | Apr 06, 2021 |
Drugs and Companies using RUCAPARIB CAMSYLATE ingredient
NCE-1 date: 19 December, 2020
Market Authorisation Date: 19 December, 2016
Treatment: A method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation
Dosage: TABLET;ORAL
RUBRACA family patents
95. Soliqua 100/33 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9950039 | SANOFI-AVENTIS US | Insulin glargine/lixisenatide fixed ratio formulation |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: Improvement in glycemic control in adults with type 2 diabetes mellitus inadequately controlled by lixisenatide in combination with metformin and a second oral antidiabetic drug
Dosage: SOLUTION;SUBCUTANEOUS
SOLIQUA 100/33 family patents
96. Solosec patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11000507 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(11 years from now) | |
| US11000508 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(11 years from now) | |
| US10849884 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(11 years from now) | |
| US10857133 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(11 years from now) | |
| US10682338 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(11 years from now) | |
| US11324721 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(11 years from now) | |
| US10335390 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(11 years from now) | |
| US11020377 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(11 years from now) | |
| US11602522 | LUPIN | Secnidazole for use in the treatment of sexually transmitted infection |
Sep, 2035
(11 years from now) | |
| US11684607 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2022 |
| New Indication(I-866) | Jun 30, 2024 |
| New Patient Population(NPP) | Jan 26, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 15, 2027 |
Drugs and Companies using SECNIDAZOLE ingredient
NCE-1 date: 15 September, 2026
Market Authorisation Date: 15 September, 2017
Treatment: Treatment of bacterial vaginosis in adult women; Treatment of trichomoniasis in patients 12 years of age and older; Treatment of bacterial vaginosis in female patients 12 years of age and older
Dosage: GRANULE;ORAL
SOLOSEC family patents
97. Sotylize patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9724297 | AZURITY | Sotalol compositions and uses of the same |
Aug, 2035
(11 years from now) | |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2014
Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently ...
Dosage: SOLUTION;ORAL
SOTYLIZE family patents
98. Spinraza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10436802 | BIOGEN IDEC | Methods for treating spinal muscular atrophy |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-226) | May 14, 2021 |
| Orphan Drug Exclusivity(ODE-127) | Dec 23, 2023 |
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
NCE-1 date: 23 December, 2020
Market Authorisation Date: 23 December, 2016
Treatment: Treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna
Dosage: SOLUTION;INTRATHECAL
SPINRAZA family patents
99. Spravato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11173134 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) | |
| US10869844 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) | |
| US11311500 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE*(NCE*) | Mar 05, 2024 |
| New Indication(I-840) | Jul 31, 2023 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered...
Dosage: SPRAY;NASAL
SPRAVATO family patents
100. Spy Agent Green Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10631746 | NOVADAQ TECH | Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography |
Aug, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-911) | Jun 05, 2026 |
| New Product(NP) | Nov 21, 2021 |
Drugs and Companies using INDOCYANINE GREEN ingredient
Market Authorisation Date: 21 November, 2018
Treatment: Measuring time-varying change in blood in a tissue volume using modified beer-lambert law in vascular, gastrointestinal, organ transplant, and plastic, micro- and reconstructive, including minimally i...
Dosage: POWDER;INTRAVENOUS, INTERSTITIAL
SPY AGENT GREEN KIT family patents
101. Sublocade patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11839611 | INDIVIOR | Buprenorphine dosing regimens |
Nov, 2035
(11 years from now) | |
| US11000520 | INDIVIOR | Buprenorphine dosing regimens |
Nov, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 30, 2020 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 November, 2017
Treatment: Treating opioid use disorder
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
SUBLOCADE family patents
102. Symdeko (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10206877 | VERTEX PHARMS INC | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
Apr, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-173) | Feb 12, 2025 |
| Orphan Drug Exclusivity(ODE-247) | Jun 21, 2026 |
| Orphan Drug Exclusivity(ODE-335) | Dec 21, 2027 |
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2023 |
| New Patient Population(NPP) | Jun 21, 2022 |
Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient
NCE-1 date: 12 February, 2022
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of cystic fibrosis in patients age 12 and older, who have two copies of the f508del mutation or at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of...
Dosage: TABLET;ORAL
SYMDEKO (COPACKAGED) family patents
103. Tabrecta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10596178 | NOVARTIS PHARM | Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 06, 2025 |
| Orphan Drug Exclusivity(ODE-291) | May 06, 2027 |
Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient
NCE-1 date: 06 May, 2024
Market Authorisation Date: 06 May, 2020
Treatment: NA
Dosage: TABLET;ORAL
TABRECTA family patents
104. Tagrisso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183020 | ASTRAZENECA | Pharmaceutical compositions comprising AZD9291 |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-176) | Apr 18, 2025 |
| Orphan Drug Exclusivity(ODE-337) | Dec 18, 2027 |
| Orphan Drug Exclusivity(ODE-102) | Nov 13, 2022 |
| New Indication(I-774) | Apr 18, 2021 |
| New Indication(I-853) | Dec 18, 2023 |
| Orphan Drug Exclusivity(ODE) | Nov 13, 2022 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2020 |
Drugs and Companies using OSIMERTINIB MESYLATE ingredient
NCE-1 date: 14 November, 2019
Market Authorisation Date: 13 November, 2015
Treatment: Adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations
Dosage: TABLET;ORAL
TAGRISSO family patents
105. Tazverik patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9889138 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(11 years from now) | |
| US10369155 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(11 years from now) | |
| US10786511 | EPIZYME INC | Method for treating cancer |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
| Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
| Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
| New Indication(I-835) | Jun 18, 2023 |
| New Indication(I-836) | Jun 18, 2023 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating relapsed or refractory follicular lymphoma; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation
Dosage: TABLET;ORAL
TAZVERIK family patents
106. Tecfidera patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10391160 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(10 years from now) | |
| US10555993 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(10 years from now) | |
| US10994003 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(10 years from now) | |
| US11246850 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US10959972 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US11129806 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US11007167 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US11007166 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-260) | Feb 05, 2023 |
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2018 |
Drugs and Companies using DIMETHYL FUMARATE ingredient
NCE-1 date: 27 March, 2017
Market Authorisation Date: 27 March, 2013
Treatment: Method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine; Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
TECFIDERA family patents
107. Tibsovo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799490 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(10 years from now) | |
| US10449184 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(10 years from now) | |
| US9968595 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
| Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
| New Indication(I-875) | Aug 25, 2024 |
| New Indication(I-924) | Oct 24, 2026 |
| Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
| Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
| New Indication(I-893) | May 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
| New Indication(I-816) | May 02, 2022 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and where the...
Dosage: TABLET;ORAL
TIBSOVO family patents
108. Toujeo Max Solostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10369291 | SANOFI US SERVICES | Mechanism for a drug delivery device |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
TOUJEO MAX SOLOSTAR family patents
109. Toujeo Solostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10369291 | SANOFI US SERVICES | Mechanism for a drug delivery device |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
TOUJEO SOLOSTAR family patents
110. Trikafta (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11426407 | VERTEX PHARMS INC | Modulators of cystic fibrosis transmembrane conductance regulator |
Oct, 2035
(11 years from now) | |
| US10758534 | VERTEX PHARMS INC | NA |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 26 April, 2023
Treatment: Treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data with a compound of claim...
Dosage: GRANULES;ORAL; TABLET;ORAL
TRIKAFTA (COPACKAGED) family patents
111. Tyrvaya patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11224598 | OYSTER POINT PHARMA | Methods of increasing lacrimal proteins |
Oct, 2035
(11 years from now) | |
| US9532944 | OYSTER POINT PHARMA | Methods of improving ocular discomfort |
Oct, 2035
(11 years from now) | |
| US9597284 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(11 years from now) | |
| US10456396 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(11 years from now) | |
| US9504644 | OYSTER POINT PHARMA | Methods of increasing tear production |
Oct, 2035
(11 years from now) | |
| US9504645 | OYSTER POINT PHARMA | Pharmaceutical formulations for treating ocular conditions |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 15, 2024 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SPRAY;NASAL
TYRVAYA family patents
112. Tyvaso Dpi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10421729 | UNITED THERAP | Microcrystalline diketopiperazine compositions and methods |
Apr, 2035
(10 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: NA
Dosage: POWDER;INHALATION
TYVASO DPI family patents
113. Ubrelvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: NA
Dosage: TABLET;ORAL
UBRELVY family patents
114. Ukoniq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9969740 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) | |
| US10414773 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10947244 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 05, 2026 |
| Orphan Drug Exclusivity(ODE-343) | Feb 05, 2028 |
| Orphan Drug Exclusivity(ODE-344) | Feb 05, 2028 |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
NCE-1 date: 05 February, 2025
Market Authorisation Date: 05 February, 2021
Treatment: Relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one pri...
Dosage: TABLET;ORAL
UKONIQ family patents
115. Vancomycin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11000567 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10849956 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10188697 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10039804 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US11517609 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
Drugs and Companies using VANCOMYCIN ingredient
Market Authorisation Date: 26 August, 2021
Treatment: Method of treating bacterial infections
Dosage: SOLUTION;INTRAVENOUS, ORAL
VANCOMYCIN family patents
116. Vancomycin Hydrochloride patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11628200 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10849956 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10039804 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US11517609 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10188697 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 15 February, 2019
Treatment: Method of treating bacterial infections
Dosage: SOLUTION;INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE family patents
117. Vasostrict patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9925233 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9981006 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9925234 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9375478 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9687526 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US10010575 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9919026 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9937223 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9750785 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9962422 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9744239 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9744209 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9968649 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9974827 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
Drugs and Companies using VASOPRESSIN ingredient
Market Authorisation Date: 17 April, 2014
Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines
Dosage: SOLUTION;INTRAVENOUS
VASOSTRICT family patents
118. Veklury patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9949994 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(11 years from now) | |
| US9724360 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
| New Patient Population(NPP) | Apr 25, 2025 |
| New Dosing Schedule(D-183) | Jan 21, 2025 |
| M(M-301) | Jul 13, 2026 |
| Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS; POWDER;INTRAVENOUS
VEKLURY family patents
119. Velphoro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11446252 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(11 years from now) | |
|
US11234938 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(11 years from now) | |
|
US10624855 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 27, 2016 |
Drugs and Companies using FERRIC OXYHYDROXIDE ingredient
Market Authorisation Date: 27 November, 2013
Treatment: NA
Dosage: TABLET, CHEWABLE;ORAL
VELPHORO family patents
120. Viekira Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9333204 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
| US9744170 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
| US10105365 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination
Dosage: TABLET, EXTENDED RELEASE;ORAL
VIEKIRA XR family patents
121. Vitrakvi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10172861 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10813936 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| US10285993 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| US9782414 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: Method of treating lung cancer, undifferentiated sarcoma, or colorectal cancer that exhibits an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating s...
Dosage: CAPSULE;ORAL
VITRAKVI family patents
122. Vitrakvi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10172861 | BAYER HEALTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9782414 | BAYER HEALTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: Method of treating solid tumors that exhibit an ntrk fusion gene in a pediatric patient
Dosage: SOLUTION;ORAL
VITRAKVI family patents
123. Vivlodex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9808468 | ICEUTICA OPERATIONS | Formulation of meloxicam |
Mar, 2035
(10 years from now) | |
| US9649318 | ICEUTICA OPERATIONS | Formulation of meloxicam |
Mar, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2018 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 22 October, 2015
Treatment: Management of osteoarthritis pain by administering 5 mg of meloxicam
Dosage: CAPSULE;ORAL
VIVLODEX family patents
124. Vyndamax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9770441 | FOLDRX PHARMS | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
Aug, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2024 |
| Orphan Drug Exclusivity(ODE-237) | May 03, 2026 |
Drugs and Companies using TAFAMIDIS ingredient
NCE-1 date: 04 May, 2023
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE;ORAL
VYNDAMAX family patents
125. Xacduro (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376499 | ENTASIS THERAP | Combination therapy for treatment of resistant bacterial infections |
Nov, 2035
(11 years from now) | |
| US9968593 | ENTASIS THERAP | Combination therapy for treatment of resistant bacterial infections |
Nov, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | May 23, 2033 |
Drugs and Companies using DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM ingredient
NCE-1 date: 23 May, 2032
Market Authorisation Date: 23 May, 2023
Treatment: Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp)
Dosage: POWDER;INTRAVENOUS
XACDURO (COPACKAGED) family patents
126. Xenoview patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10583205 | POLAREAN | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices |
Feb, 2035
(10 years from now) | |
| US11052161 | POLAREAN | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2027 |
Drugs and Companies using XENON XE-129 HYPERPOLARIZED ingredient
NCE-1 date: 23 December, 2026
Market Authorisation Date: 23 December, 2022
Treatment: NA
Dosage: GAS;INHALATION
XENOVIEW family patents
127. Xhance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10300229 | OPTINOSE US INC | Nasal delivery devices |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway
Dosage: SPRAY, METERED;NASAL
XHANCE family patents
128. Xpovio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10519139 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(11 years from now) | |
| US11807629 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11746102 | KARYOPHARM THERAPS | Polymorphs of selinexor |
Aug, 2035
(11 years from now) | |
| US11753401 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Jul 03, 2026 |
| Orphan Drug Exclusivity(ODE-257) | Jul 03, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2024 |
| Orphan Drug Exclusivity(ODE-310) | Jun 22, 2027 |
| Orphan Drug Exclusivity(ODE-346) | Dec 18, 2027 |
| New Indication(I-837) | Jun 22, 2023 |
Drugs and Companies using SELINEXOR ingredient
NCE-1 date: 04 July, 2023
Market Authorisation Date: 03 July, 2019
Treatment: Xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Dosage: TABLET;ORAL
XPOVIO family patents
129. Xyosted (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10912782 | ANTARES PHARMA INC | Needle assisted injection administration of testosterone compositions |
Feb, 2035
(10 years from now) | |
| US10238662 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Feb, 2035
(10 years from now) | |
| US11813435 | ANTARES PHARMA INC | Needle assisted injection device having reduced trigger force |
Feb, 2035
(10 years from now) | |
| US11191908 | ANTARES PHARMA INC | Syringe shock absorber for use in an injection device |
Oct, 2035
(11 years from now) | |
| US9744302 | ANTARES PHARMA INC | Needle assisted jet injection device having reduced trigger force |
Nov, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2021 |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Method of administering testosterone enanthate subcutaneously
Dosage: SOLUTION;SUBCUTANEOUS
XYOSTED (AUTOINJECTOR) family patents
130. Ycanth patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11052064 | VERRICA PHARMS | Compositions, methods and systems for the treatment of cutaneous disorders |
May, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 21, 2028 |
Drugs and Companies using CANTHARIDIN ingredient
NCE-1 date: 22 July, 2027
Market Authorisation Date: 21 July, 2023
Treatment: Topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older
Dosage: SOLUTION;TOPICAL
YCANTH family patents
131. Zegalogue patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10442847 | ZEALAND PHARMA | Glucagon analogues |
Feb, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2026 |
Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient
NCE-1 date: 22 March, 2025
Market Authorisation Date: 22 March, 2021
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
ZEGALOGUE family patents
132. Zegalogue (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10442847 | ZEALAND PHARMA | Glucagon analogues |
Feb, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2026 |
Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient
NCE-1 date: 22 March, 2025
Market Authorisation Date: 22 March, 2021
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
ZEGALOGUE (AUTOINJECTOR) family patents
133. Zerbaxa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10125149 | CUBIST PHARMS LLC | Synthesis of cephalosporin compounds |
Aug, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Patient Population(NPP) | Apr 21, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Dec 19, 2024 |
Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient
NCE-1 date: 20 December, 2023
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: POWDER;INTRAVENOUS
ZERBAXA family patents
134. Zilbrysq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10106579 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US11014965 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10435438 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10208089 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10562934 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752190 | UCB INC | Modulators of complement activity |
Jun, 2035
(11 years from now) | |
| US11535650 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10835574 | UCB INC | Modulators of complement activity |
Jun, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 17, 2028 |
| Orphan Drug Exclusivity(ODE-446) | Oct 17, 2030 |
Drugs and Companies using ZILUCOPLAN SODIUM ingredient
NCE-1 date: 18 October, 2027
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of generalized myasthenia gravis (gmg) in an adult patient who is anti-acetylcholine receptor (achr) antibody positive by subcutaneous administration of c5 complement inhibitor zilucoplan
Dosage: SOLUTION;SUBCUTANEOUS
ZILBRYSQ family patents
135. Zingo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358338 | POWDER PHARMS | Particle cassettes and processes therefor |
Apr, 2035
(11 years from now) | |
| US9370622 | POWDER PHARMS | Devices and methods for delivering particles |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 08, 2012 |
Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 August, 2007
Treatment: Zingo is a powder intradermal system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action
Dosage: SYSTEM;INTRADERMAL
ZINGO family patents
136. Zituvio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10925871 | ZYDUS | Pharmaceutical compositions of sitagliptin |
Feb, 2035
(10 years from now) | |
Drugs and Companies using SITAGLIPTIN ingredient
Market Authorisation Date: 18 October, 2023
Treatment: NA
Dosage: TABLET;ORAL
ZITUVIO family patents
137. Zynrelef Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10213510 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US10898575 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US10980886 | HERON THERAPS INC | Compositions of a polyorthoester and an organic acid excipient |
Apr, 2035
(10 years from now) | |
| US11413350 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US9801945 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US10632199 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US10098957 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US9694079 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US11083797 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US11083730 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 12, 2024 |
| New Indication(I-933) | Jan 23, 2027 |
Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient
Market Authorisation Date: 12 May, 2021
Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarti...
Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR
ZYNRELEF KIT family patents
List of large molecules
1. List of Tysabri large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10023831 | BIOGEN INC. | Gas delivery devices and associated systems and methods |
Mar, 2035
(10 years from now) | |
| US11124760 | BIOGEN INC. | Methods for overcoming glutamine deprivation during mammalian cell culture |
Aug, 2035
(11 years from now) |
Ingredients: NATALIZUMAB
2. List of Avastin large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10274466 | GENENTECH, INC. | Elucidation of ion exchange chromatography input optimization |
Jul, 2035
(11 years from now) | |
| US10208355 | GENENTECH, INC. | Method of treatment for glioblastoma by administering a VEGF antagonist |
Jul, 2035
(11 years from now) | |
| US10336983 | GENENTECH, INC. | Method for increasing the specific production rate of eukaryotic cells |
Jul, 2035
(11 years from now) |
Ingredients: BEVACIZUMAB
3. List of Eylea large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9816110 | REGENERON PHARMACEUTICALS, INC. | CHO integration sites and uses thereof |
Oct, 2035
(11 years from now) | |
| USD906102 | REGENERON PHARMACEUTICALS, INC. | Packaging |
Dec, 2035
(11 years from now) |
Ingredients: AFLIBERCEPT
4. List of Lucentis large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10112994 | GENENTECH, INC. | Methods of producing two chain proteins in bacteria |
Nov, 2035
(11 years from now) |
Ingredients: RANIBIZUMAB